Aptamers to the human il-12 cytokine family and their use as...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 48/00 (2006.01) C07K 14/715 (2006.01) C08G 63/91 (2006.01)

Patent

CA 2623424

The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of binding to human IL-23 and/or human IL- 12 cytokines and thus modulate their biological activity and are useful as therapeutic agents in immune, auto-immune and cancer therapeutics.

La présente invention concerne des substances et des méthodes de traitement de maladies auto-immunes dans la pathogénèse desquelles sont impliquées des cytokines. Ces substances et méthodes conviennent pour le traitement de maladies auto-immunes. Sont concernés de ligands d'acides nucléiques capables de se lier aux cytokines humaines IL-23 et/ou aux cytokines humaines IL- 12 et donc de moduler leur activité biologique. Ces ligands sont utiles comme agents thérapeutiques dans le traitement des maladies auto-immunes et du cancer.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Aptamers to the human il-12 cytokine family and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aptamers to the human il-12 cytokine family and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aptamers to the human il-12 cytokine family and their use as... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1658626

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.